Posted by Michael Wonder on 19 Aug 2025
Valneva’s chikungunya vaccine Ixchiq now authorised in Canada for individuals aged 12 and plder
18 August 2025 - Valneva today announced that Health Canada has granted marketing authorisation for its single dose vaccine, Ixchiq, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older.
This announcement adds to the adult marketing authorisation already received in Canada and complements the adolescent label extension received in Europe in April 2025.
